強
強気
強気 · 25%VKTX
$29.25
シナリオ価格
$24.400
-1.352 (-5.54%)終値時点
Loading chart…
- 高値
- 25.743
- 始値
- 25.540
- 出来高加重平均価格
- 24.83
- 出来高
- 4.68M
- 時価総額
- 5.60B
- 安値
- 24.360
- 売買代金
- 116.11M
- EV/EBITDA（TTM）
- 0.00
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
AI分析 of Viking Therapeutics Inc (VKTX)
中立Viking Therapeutics Inc is currently not a strong buy due to its recent price decline and negative earnings outlook. The current price is $24.40, which is significantly lower than the analyst price targets of $85 and $120, indicating potential upside. However, the RSI is at 30.461, suggesting the stock is oversold, yet the company is projected to continue incurring losses with a forward P/E of 0 and a net income loss expected to reach -$158.3 million in Q1 2026. The main risk is the ongoing cash burn and potential clinical trial failures, which could further impact stock performance.
アナリスト評価（3）
上値余地 +297.54%
買い
3 買い
0 中立
0 売り
現在: 24.40
安値
70.00
平均
97.00
高値
125.00
Truist
買い
$85
2026-10-07
Truist
2026-10-07
目標株価
$85
買い
Truist
買い
$87
2026-09-23
Truist
2026-09-23
目標株価
$87
買い
Oppenheimer
アウトパフォーム
$120
2026-09-22
Oppenheimer
2026-09-22
目標株価
$120
アウトパフォーム
H.C. Wainwright
買い
$102
2026-09-22
H.C. Wainwright
2026-09-22
目標株価
$102
買い
Morgan Stanley
オーバーウェイト
$95
2026-09-22
Morgan Stanley
2026-09-22
目標株価
$95
オーバーウェイト
バリュエーション指標
Viking Therapeutics Inc（VKTX）の現在の予想PERは0.00で、5年平均は-19.48です。
Alphio AI による VKTX の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
VKTX を保有するクジラ
イベントタイムライン
ニュース
5.010-20FoolViking Therapeutics: Five-Year Growth Prospects
9.010-20NASDAQ.COMViking Initiates Phase 3 Trials for VK2735
9.010-20FoolViking Therapeutics Initiates Phase 3 Trials for VK2735 Oral Formulation
8.510-18FoolViking Therapeutics Raises $575 Million to Fund Trials
8.510-14stocktwitsViking Launches Phase 3 Trials for VK2735 Weight Loss Drug
VKTX のよくある質問 — Alphio AI が回答
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Viking Therapeutics Inc is currently not a strong buy due to its recent price decline and negative earnings outlook. The current price is $24.40, which is significantly lower than the analyst price targets of $85 and $120, indicating potential upside. However, the RSI is at 30.461, suggesting the stock is oversold, yet the company is projected to continue incurring losses with a forward P/E of 0 and a net income loss expected to reach -$158.3 million in Q1 2026. The main risk is the ongoing cash burn and potential clinical trial failures, which could further impact stock performance.
3 analysts cover VKTX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 97.00.
コミュニティ
もっと見る ↗
👀 Looking for the bigger upside in obesity stocks? $NVO vs. $VKTX Novo Nordisk has blockbuster drugs and an established commercial business. Viking Therapeutics is betting on a different opportunity: turning VK2735 into a contender in both oral and injectable obesity treatments. 🔥 Why $VKTX could stand out: 💊 Oral and injectable VK2735 now in Phase 3 📊 Maintenance data showed 90% of prior weight loss retained with every-other-week dosing and 85% with monthly dosing 🚀 A potential differentiator in long-term weight management ⚠️ The trade-off? VKTX has no marketed products yet, making it a higher-risk bet than NVO. 🎯 Which obesity stock offers the better opportunity? Compare the bull case for $VKTX vs. $NVO here 👇
もっと見る
🚨 $VKTX just took a major step toward bringing its obesity pill to market! Viking Therapeutics has initiated two Phase 3 trials of oral VK2735, targeting patients with obesity both with and without Type 2 diabetes. 📊 Phase 2 results showed up to 12.2% mean weight loss in just 13 weeks, versus 1.3% with placebo. 🔥 The bigger picture? > Injectable VK2735 is already in Phase 3, with enrollment completed in both studies. > Maintenance data showed patients retained 85–90% of prior weight loss with less frequent injections. > Oral maintenance research and VK3019 add further potential to the pipeline. Competition from $LLY and $NVO is heating up, but Viking is expanding its options across oral, injectable and maintenance treatments.
もっと見る
$VKTX Bouncing off yearly support and downtrend line Need some rotation back into Biotech names as AI names sell off Reclaim of 30 will be next pivot Our long term conviction hold at Tenet Research
もっと見る
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。